Parkinson's Disease Related Research Tools
Parkinson's disease (PD) is the most common neurodegenerative movement disorder. Pathologically, PD is characterized by the presence of abnormal intra-neuronal aggregates of α-synuclein (SNCA). SNCA is central to the pathogenesis of PD, as is highlighted by the fact that rare SNCA mutations, duplications, or triplications cause autosomal dominant familial PD. The etiology of idiopathic PD is multifactorial, likely arising from a combination of polygenic inheritance, environmental exposures, and gene-environment interactions. The current medical management of PD aims at controlling signs and symptoms as long as possible while minimizing adverse effects. Most of them are targeting at supplementation of dopamine to the brain to alleviate motor dysfunction caused by the degeneration of dopaminergic neurons in the nigrostriatal system.
Numerous potential therapies for PD are at various stages of preclinical and clinical testing. These agents target many aspects of PD pathogenesis. Several basic pathophysiological pathways are depicted in Fig.1, including those that lead to Lewy bodies, and those involving inflammatory factors, mitochondrial dysfunction and oxidative stress.
Fig.1 Mechanisms of potential therapies for PD. (Elkouzi, 2019)
Genetic-based targeted therapies currently being tested in PD patients focus on SNCA, glucocerebrosidase (GBA), and leucine-rich repeat kinase (LRRK2). Multiple lines of evidence support a pivotal role of SNCA in PD pathogenesis. The presence of aggregated α-synuclein in specific brain regions suggests a central role for this protein in sporadic disorder. Heterozygous GBA mutations increase the risk of developing PD and other synucleinopathies. GBA mutations are the most frequent genetic risk factors for PD identified to date, with 7% to 10% of PD patients carrying at least 1 of approximately 300 reported GBA mutations. LRRK2 interacts with many key proteins implicated in PD, suggesting that LRRK2 may be a central player in the pathways underlying disease pathogenesis. The current leading hypothesis shows that increased kinase activity by LRRK2 mutations is responsible for PD. The popular targets in PD researches are listed below:
SNCA | GBA | PINK1 | LRRK2 |
CYP2D6 | PRKN | VPS35 | PARK7 |
Creative Biolabs offers comprehensive products as well as high-quality customized services for various targets involved in the signaling pathway for PD research. For any customized services or products, please feel free to contact us for more information.
Reference
- Elkouzi, A.; et al. Emerging therapies in Parkinson's disease-Repurposed drugs and new approaches. Nature Reviews Neurology. 2019, 15(4): 204-223.
Target



- Species:
- Human
- Relevant Diseases:
- Parkinson's Disease


- Species:
- Human
- Relevant Diseases:
- Parkinson's Disease




This kit is designed for an accurate quantitative measurement of alpha synuclein aggregation in brain extracts.


Rabbit Monoclonal Antibody to LRRK2
- Host Species:
- Rabbit
- Species Reactivity:
- Mouse; Human
- Applications:
- ICC; IF; IHC-P; WB
- Conjugation:
- Unconjugated; APC; PE; HRP; Biotin; FITC

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Epilepsy; Parkinson's Disease

- Relevant Diseases:
- Alzheimer's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease

- Relevant Diseases:
- Parkinson's Disease



- Species:
- Human
- Cell Types:
- Neural Progenitor Cells

For the quantitative determination of human gamma-synuclein (SNCG) concentrations in serum, plasma, tissue homogenates, cell lysates.

For the quantitative determination of human synuclein, alpha (non A4 component of amyloid precursor) oligomer (SNCA oligomer) concentrations in serum, plasma.

- Species:
- Human
- Applications:
- Cell Culture
- Cell Types:
- Neural Stem Cells

- Species:
- Human
- Applications:
- Cell Culture
- Cell Types:
- Neural Stem Cells

Zyxin Rabbit Monoclonal Antibody
- Host Species:
- Rabbit
- Species Reactivity:
- Human
- Applications:
- IHC-P
- Conjugation:
- Unconjugated

alpha Internexin Rabbit Monoclonal Antibody
- Host Species:
- Rabbit
- Species Reactivity:
- Human
- Applications:
- ICC; IF; FCM; IHC-P
- Conjugation:
- Unconjugated

Anti-CAV3.2 Monoclonal Antibody
- Host Species:
- Mouse
- Species Reactivity:
- Human
- Applications:
- IF; WB; IHC; IP
- Conjugation:
- Unconjugated
- iNeuMab™ Anti-CD20 Antibody (NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- iNeuMab™ Anti-Alpha Synuclein BBB Shuttle Antibody (NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-EPHB2 Antibody (NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- iNeuMab™ Anti-FGFR1 Antibody (NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P2293) (Cat#: NRP-0422-P2293)
- iNeuMab™ Anti-pTau Antibody (NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P517) (Cat#: NRP-0422-P517)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Mouse Retinal Ganglion Cells (Cat#: NCL2110P145)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Mouse Glioma Cell Line GL-261-Luc (Cat#: NCL-2108P06)
- Rat Microglia Cell Line HAPI, Immortalized (Cat#: NCL2110P015)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)